Zusammenfassung
Das Peniskarzinom ist das Plattenepithelkarzinom des Urogenitaltraktes. Aufgrund der oberflächlichen Lokalisation ist eine Diagnose im Frühstadium möglich, tatsächlich werden viele Fälle aufgrund patientenbedingter Faktoren erst in fortgeschrittenen Stadien festgestellt. Dieses urologische Malignom ist als streng lymphogen metastasierender Tumor in lokal begrenzten Stadien operativ heilbar. Die Prognose wird entscheidend vom Status und vom Management der inguinalen Lymphknoten bestimmt. Nicht selten wird aus Sorge vor den Konsequenzen der Behandlung von therapeutischen Standards abgewichen. Bei Progression ist mit systemischer Therapie eine Heilung nur in Ausnahmefällen möglich. Aufgrund der geringen Inzidenz handelt es sich um eine „orphan disease“, in deren Erforschung wenig Mittel investiert werden, und Therapiestudien sind rar. Die klinische Praxis ist oft gekennzeichnet durch individuelle Heilversuche mit häufig schlechten Ergebnissen.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
Literatur
Agrawal A, Pai D, Ananthakrishnan N, Smile SR, Ratnakar C. The histological extent of the local spread of carcinoma of the penis and its therapeutic implications. BJU Int (2000) 85: 299–301
Austoni E, Fenice O, Kartalas Goumas Y, Colombo F, Mantovani F, Pisani E. (New trends in the surgical treatment of penile carcinoma). Arch Ital Urol Androl (1996) 68: 163–168
Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol (2007) 177: 1335–1338
Bevan-Thomas R, Slaton JW, Pettaway CA. Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol (2002) 167: 1638–1642
Bouchot O, Rigaud J, Maillet F, Hetet JF, Karam G. Morbidity of inguinal lymphadenectomy for invasive penile carcinoma. Eur Urol (2004) 45: 761–765; discussion 765–766
Brinton LA, Li JY, Rong SD et al. Risk factors for penile cancer: results from a case-control study in China. Int J Cancer (1991) 47: 504–509
Cabanas RM. An approach for the treatment of penile carcinoma. Cancer (1977) 39: 456–466
Catalona WJ. Modified inguinal lymphadenectomy for carcinoma of the penis with preservation of saphenous veins: technique and preliminary results. J Urol (1988) 140: 306–310
Corral DA, Sella A, Pettaway CA, Amato RJ, Jones DM, Ellerhorst J. Combination chemotherapy for metastatic or locally advanced genitourinary squamous cell carcinoma: a phase II study of methotrexate, cisplatin and bleomycin. J Urol (1998) 160: 1770–1774
Cubilla AL, Dillner J, Schellhammer PF, Horenblas S, Ayala AG, Reuter VE, Von Krogh G. Tumours of the penis. In: Eble JNSG, Epstein JI, Sesterhenn IA (eds) World Health Organization Classification of tumours Pathology and genetics of tumours of the urinary system and male genital organs Lyon, France: IARC Press, 2004: 280–290
Cubilla AL, Reuter V, Velazquez E, Piris A, Saito S, Young RH. Histologic classification of penile carcinoma and its relation to outcome in 61 patients with primary resection. Int J Surg Pathol (2001) 9: 111–120
Cubilla AL. The role of pathologic prognostic factors in squamous cell carcinoma of the penis. World J Urol (2009) 27: 169–177
Daling JR, Madeleine MM, Johnson LG et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer (2005) 116: 606–616
Daseler EH, Anson BJ, Reimann AF. Radical excision of the inguinal and iliac lymph glands; a study based upon 450 anatomical dissections and upon supportive clinical observations. Surg Gynecol Obstet (1948) 87: 679–694
Dexeus FH, Logothetis CJ, Sella A et al. Combination chemotherapy with methotrexate, bleomycin and cisplatin for advanced squamous cell carcinoma of the male genital tract. J Urol (1991) 146: 1284–1287
Doeberitz MK, Vinokurova S. Host factors in HPV-related carcinogenesis: cellular mechanisms controlling HPV infections. Arch Med Res (2009) 40: 435–442
Favorito LA, Nardi AC, Ronalsa M, Zequi SC, Sampaio FJ, Glina S. Epidemiologic study on penile cancer in Brazil. Int Braz J Urol (2008) 34: 587–591; discussion 591–583
Franks KN, Kancherla K, Sethugavalar B, Whelan P, Eardley I, Kiltie AE. Radiotherapy for node positive penile cancer: experience of the Leeds teaching hospitals. J Urol. 2010 186: 524–529
Gonzaga-Silva LF, Tavares JM, Freitas FC, Tomas Filho ME, Oliveira VP, Lima MV. The isolated gamma probe technique for sentinel node penile carcinoma detection is unreliable. Int Braz J Urol (2007) 33: 58–63; discussion 64–57
Haas GP, Blumenstein BA, Gagliano RG et al. Cisplatin, methotrexate and bleomycin for the treatment of carcinoma of the penis: a Southwest Oncology Group study. J Urol (1999) 161: 1823–1825
Hakenberg OW, Nippgen JB, Froehner M, Zastrow S, Wirth MP. Cisplatin, methotrexate and bleomycin for treating advanced penile carcinoma. BJU Int (2006) 98: 1225–1227
Harish K, Ravi R. The role of tobacco in penile carcinoma. Br J Urol (1995) 75: 375–377
Hegarty PK, Shabbir M, Hughes B et al. Penile preserving surgery and surgical strategies to maximize penile form and function in penile cancer: recommendations from the United Kingdom experience. World J Urol (2009) 27: 179–187
Hellberg D, Valentin J, Eklund T, Nilsson S. Penile cancer: is there an epidemiological role for smoking and sexual behaviour? Br Med J (Clin Res Ed) (1987) 295: 1306–1308
Hernandez BY, Barnholtz-Sloan J, German RR et al. Burden of invasive squamous cell carcinoma of the penis in the United States, 1998–2003. Cancer (2008) 113: 2883–2891
Hernandez-Toris N, Quintero-Becerra J, Gallegos-Hernandez JF et al. (Lymphatic mapping and sentinel node biopsy in penis cancer. Feasibility study and preliminary report). Cir Cir (2007) 75: 87–91
Horenblas S, Jansen L, Meinhardt W, Hoefnagel CA, de Jong D, Nieweg OE. Detection of occult metastasis in squamous cell carcinoma of the penis using a dynamic sentinel node procedure. J Urol (2000) 163: 100–104
Hussein AM, Benedetto P, Sridhar KS. Chemotherapy with cisplatin and 5-fluorouracil for penile and urethral squamous cell carcinomas. Cancer (1990) 65: 433438
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin (2007) 57: 43–66
Kroon BK, Horenblas S, Lont AP, Tanis PJ, Gallee MP, Nieweg OE. Patients with penile carcinoma benefit from immediate resection of clinically occult lymph node metastases. J Urol (2005) 173: 816–819
Leijte JA, Gallee M, Antonini N, Horenblas S. Evaluation of current TNM classification of penile carcinoma. J Urol (2008) 180: 933–938; discussion 938
Leijte JA, Kerst JM, Bais E, Antonini N, Horenblas S. Neoadjuvant chemotherapy in advanced penile carcinoma. Eur Urol (2007) 52: 488–494
Leijte JA, Kirrander P, Antonini N, Windahl T, Horenblas S. Recurrence patterns of squamous cell carcinoma of the penis: recommendations for follow-up based on a two-centre analysis of 700 patients. Eur Urol (2008) 54: 161–168
Leijte JA, Kroon BK, Valdes Olmos RA, Nieweg OE, Horenblas S. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol (2007) 52: 170–177
Leis PF, Stevens KR, Baer SC, Kadmon D, Goldberg LH, Wang XJ. A c-rasHa mutation in the metastasis of a human papillomavirus (HPV)-18 positive penile squamous cell carcinoma suggests a cooperative effect between HPV-18 and c-rasHa activation in malignant progression. Cancer (1998) 83: 122–129
Lont AP, Gallee MP, Meinhardt W, van Tinteren H, Horenblas S. Penis conserving treatment for T1 and T2 penile carcinoma: clinical implications of a local recurrence. J Urol (2006) 176: 575–580; discussion 580
Lont AP, Kroon BK, Gallee MP, van Tinteren H, Moonen LM, Horenblas S. Pelvic lymph node dissection for penile carcinoma: extent of inguinal lymph node involvement as an indicator for pelvic lymph node involvement and survival. J Urol (2007) 177: 947–952; discussion 952
Madsen BS, van den Brule AJ, Jensen HL, Wohlfahrt J, Frisch M. Risk factors for squamous cell carcinoma of the penis – population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev (2008) 17: 2683–2691
Martins AC, Faria SM, Cologna AJ, Suaid HJ, Tucci S Jr. Immunoexpression of p53 protein and proliferating cell nuclear antigen in penile carcinoma. J Urol (2002) 167: 89–92; discussion 92–83
Minhas S, Kayes O, Hegarty P, Kumar P, Freeman A, Ralph D. What surgical resection margins are required to achieve oncological control in men with primary penile cancer? BJU Int (2005) 96: 1040–1043
Misra S, Chaturvedi A, Misra NC. Penile carcinoma: a challenge for the developing world. Lancet Oncol (2004) 5: 240–247
Narayana AS, Olney LE, Loening SA, Weimar GW, Culp DA. Carcinoma of the penis: analysis of 219 cases. Cancer (1982) 49: 2185–2191
Necchi A, Nicolai N, Colecchia M et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol. 2011 29: 650–652
Ornellas AA, Kinchin EW, Nobrega BL, Wisnescky A, Koifman N, Quirino R. Surgical treatment of invasive squamous cell carcinoma of the penis: Brazilian National Cancer Institute long-term experience. J Surg Oncol (2008) 97: 487–495
Pagliaro LC, Williams DL, Daliani D et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010 28: 3851–3857
Parkin DM WS, Ferlay J, Teppo L, Thomas DB (ed). Cancer Incidence in Five Continents. IARC Scientific Publications No155 Lyon, France: IARC, 2002
Persson B, Sjodin JG, Holmberg L, Windahl T. The National Penile Cancer Register in Sweden 2000–2003. Scand J Urol Nephrol (2007) 41: 278–282
Pizzocaro G, Algaba F, Horenblas S et al. EAU Penile Cancer Guidelines 2009. Eur Urol
Pizzocaro G, Nicolai N, Milani A. Taxanes in Combination with Cisplatin and Fluorouracil for Advanced Penile Cancer: Preliminary Results. Eur Urol. 2008
Pizzocaro G, Piva L, Bandieramonte G, Tana S. Up-to-date management of carcinoma of the penis. Eur Urol (1997) 32: 5–15
Pizzocaro G, Piva L. Adjuvant and neoadjuvant vincristine, bleomycin, and methotrexate for inguinal metastases from squamous cell carcinoma of the penis. Acta Oncol (1988) 27: 823–824
Poetsch M, Schuart BJ, Schwesinger G, Kleist B, Protzel C. Screening of microsatellite markers in penile cancer reveals differences between metastatic and nonmetastatic carcinomas. Mod Pathol (2007) 20: 1069–1077
Poetsch M, Hemmerich M, Kakies C et al. Alterations in the tumor suppressor gene p16(INK4A) are associated with aggressive behavior of penile carcinomas. Virchows Arch (2011) 458: 221–229
Protzel C, Alcaraz A, Horenblas S, Pizzocaro G, Zlotta A, Hakenberg OW. Lymphadenectomy in the surgical management of penile cancer. Eur Urol (2009) 55: 1075–1088
Protzel C, Hakenberg OW. Chemotherapy in patients with penile carcinoma. Urol Int (2009) 82: 1–7
Protzel C, Kakies C, Kleist B, Poetsch M, Giebel J. Down-regulation of the metastasis suppressor protein KAI1/CD82 correlates with occurrence of metastasis, prognosis and presence of HPV DNA in human penile squamous cell carcinoma. Virchows Arch (2008) 452: 369–375
Ravi R. Morbidity following groin dissection for penile carcinoma. Br J Urol (1993) 72: 941–945
Rubin MA, Kleter B, Zhou M et al. Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol (2001) 159: 1211–1218
Saisorn I, Lawrentschuk N, Leewansangtong S, Bolton DM. Fine-needle aspiration cytology predicts inguinal lymph node metastasis without antibiotic pretreatment in penile carcinoma. BJU Int (2006) 97: 1225–1228
Sastre-Garau X, Favre M, Couturier J, Orth G. Distinct patterns of alteration of myc genes associated with integration of human papillomavirus type 16 or type 45 DNA in two genital tumours. J Gen Virol (2000) 81: 1983–1993
Schlenker B, Gratzke C, Seitz M et al. Fluorescence-guided laser therapy for penile carcinoma and precancerous lesions: Long-term follow-up. Urol Oncol. 2009
Schlenker B, Tilki D, Seitz M et al. Organ-preserving neodymium-yttrium-aluminium-garnet laser therapy for penile carcinoma: a long-term follow-up. BJU Int. 2010 106: 786–790
Sobin LH, Gospodariwicz M, Wittekind C (eds). TNM Classification of malignant tumours. UICC International Union Against Cancer, 7th edn. New York: Wiley-Blackwell 2009
Theodore C, Skoneczna I, Bodrogi I et al. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992). Ann Oncol. 2008
Velazquez EF, Barreto JE, Rodriguez I, Piris A, Cubilla AL. Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol (2004) 12: 139–146
Young R SJ, Amin M, Ulbright T, Cubilla A. Tumors of the prostate gland, seminal vesicles, male urethra and penis. In: Rosai J. SL, ed. Atlas of Tumor Pathology. Washington, D.C., USA: Armed Forces Institute of Pathology, 2000: 1–334
Zhu Y, Li H, Yao XD et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int. 2010 85: 334–340
zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology (2009) 384: 260–265
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Protzel, C., Hakenberg, O. (2014). Peniskarzinom. In: Rübben, H. (eds) Uroonkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-35032-0_26
Download citation
DOI: https://doi.org/10.1007/978-3-642-35032-0_26
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-35031-3
Online ISBN: 978-3-642-35032-0
eBook Packages: Medicine (German Language)